Two versus three to four cycles of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice
Two cycles of neoadjuvant immunochemotherapy can be considered in locally advanced ESCC at high risk of developing toxicity with 3-4 cycles with similar oncologic outcomes.
Authors
- Christopher J. Anker (ORCID: https://orcid.org/0000-0002-3230-1815)
- Weiyu Shen (ORCID: https://orcid.org/0009-0007-3870-6534)
- José M. Pimiento (ORCID: https://orcid.org/0000-0002-7237-4509)
- Hongyan Yu
- Gaofeng Liang (ORCID: https://orcid.org/0000-0003-0097-0296)
- Kazuo Koyanagi (ORCID: https://orcid.org/0000-0002-8010-8630)
- Jinxian He
- Jian Hu (ORCID: https://orcid.org/0009-0006-0873-2507)
- Jia-Cong Liu
Institutions
- Ningbo University (CN)
- Tokai University (JP)
- Moffitt Cancer Center (US)
- Ningbo Medical Center Lihuili Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/jtd-24-1365
- Citations
- 5
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- American College of Surgeons
- Astellas Pharma
- Natural Science Foundation of Ningbo
- National Key Research and Development Program of China
- Natural Science Foundation of Zhejiang Province
- Science and Technology Program of Zhejiang Province